Large-Scale Compounding Operations May Be A “Loophole” For Counterfeits, Slobodin Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The House Energy & Commerce counsel says that some compounding operations now resemble manufacturing facilities rather than pharmacies.
You may also be interested in...
Grassley Seeks FDA, CMS Clarification On Drug Compounding
In a letter to both agencies, Grassley asks FDA to what extent the federal government should assume oversight of drug compounding.
Compounding Pharmacists Group Issues Uniform Labeling Guidelines
Guidelines are latest response to Wyeth’s claim that compounders are manufacturing copies of Premarin.
Celgene To Submit Revlimid Phase III Special Protocol Assessment For CLL To FDA Shortly
Firm notes strong uptake of the product in 2006, as well as more than $400 million in Thalomid sales for the year during earnings call.